NO20035056D0 - Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes - Google Patents

Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes

Info

Publication number
NO20035056D0
NO20035056D0 NO20035056A NO20035056A NO20035056D0 NO 20035056 D0 NO20035056 D0 NO 20035056D0 NO 20035056 A NO20035056 A NO 20035056A NO 20035056 A NO20035056 A NO 20035056A NO 20035056 D0 NO20035056 D0 NO 20035056D0
Authority
NO
Norway
Prior art keywords
diabetes
treatment
insulin resistance
resistance syndrome
adenosine analogues
Prior art date
Application number
NO20035056A
Other languages
English (en)
Norwegian (no)
Inventor
Andreas Herling
Gerhard Jaehne
Michael R Myers
Martin P Maguire
Alfred P Spade
William R Ewing
Henry W Pauls
Yong-Mi Choi-Sledeski
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20035056D0 publication Critical patent/NO20035056D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20035056A 2001-05-14 2003-11-13 Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes NO20035056D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
NO20035056D0 true NO20035056D0 (no) 2003-11-13

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035056A NO20035056D0 (no) 2001-05-14 2003-11-13 Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes

Country Status (23)

Country Link
US (1) US20030176390A1 (xx)
EP (2) EP1258247A1 (xx)
JP (1) JP2004533448A (xx)
KR (1) KR20040002962A (xx)
CN (1) CN1518450A (xx)
BG (1) BG108356A (xx)
BR (1) BR0209650A (xx)
CA (1) CA2447408A1 (xx)
CO (1) CO5540288A2 (xx)
CZ (1) CZ20033079A3 (xx)
EA (1) EA007253B1 (xx)
EE (1) EE200300551A (xx)
HR (1) HRP20030928A2 (xx)
HU (1) HUP0400464A3 (xx)
IL (1) IL158794A0 (xx)
MX (1) MXPA03010336A (xx)
NO (1) NO20035056D0 (xx)
NZ (1) NZ529390A (xx)
PL (1) PL364573A1 (xx)
SK (1) SK14052003A3 (xx)
WO (1) WO2002092093A1 (xx)
YU (1) YU90203A (xx)
ZA (1) ZA200308777B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
NZ529390A (en) 2006-06-30
JP2004533448A (ja) 2004-11-04
ZA200308777B (en) 2006-04-26
YU90203A (sh) 2006-08-17
KR20040002962A (ko) 2004-01-07
EP1404338A1 (en) 2004-04-07
BG108356A (bg) 2004-12-30
CA2447408A1 (en) 2002-11-21
US20030176390A1 (en) 2003-09-18
HUP0400464A2 (hu) 2004-07-28
PL364573A1 (en) 2004-12-13
BR0209650A (pt) 2004-07-13
HRP20030928A2 (en) 2005-10-31
IL158794A0 (en) 2004-05-12
CO5540288A2 (es) 2005-07-29
MXPA03010336A (es) 2004-03-16
WO2002092093A1 (en) 2002-11-21
EP1258247A1 (en) 2002-11-20
EA200301231A1 (ru) 2004-04-29
CZ20033079A3 (cs) 2004-08-18
EE200300551A (et) 2004-02-16
CN1518450A (zh) 2004-08-04
EA007253B1 (ru) 2006-08-25
HUP0400464A3 (en) 2007-03-28
SK14052003A3 (sk) 2004-07-07

Similar Documents

Publication Publication Date Title
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
DK1183020T3 (da) (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
ZA200402688B (en) Method and composition for preventing or reducing the symptons of insulin resistance syndrome.
NO20030832D0 (no) Kondenserte cykliske forbindelser og medisinsk anvendelse derav
DK1309324T3 (da) Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
DE60236010D1 (de) Kalibrierung der gewebedichte in der computertomographie
NO20044272L (no) Legemiddel for behandling og/eller forebyggelse av kronisk avstotning
AU2003297060A1 (en) Vibratory venous and arterial oximetry sensor
NO20035056D0 (no) Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes
NO20035157D0 (no) Lungeadministrering av kjemisk modifisert insulin
DE60237823D1 (de) Medizinisches behandlungsinstrument
DE60322507D1 (de) Steuerbarer katheter oder dergleichen
DK1581297T3 (da) Kateter med enhedsbestanddel
IS7189A (is) Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression